Xue Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xue Chen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Xiangjian Luo
Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China
4 shared publications Ann M. Bode
The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
2 shared publicationsJianfu Heng
Department of Clinical Pharmaceutical Research Institution, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China
2 shared publicationsQian Liu
Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, PR China; Key Laboratory of Carcinogenesis and Invasion, Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan 410078, PR China
2 shared publicationsFeng Yang
Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
1 shared publication- Feng Yang
Department of Clinical Pharmaceutical Research Institution, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Scientific Reports
EBV-LMP1 stabilizes circadian CRY2 to drive immune escape and chemoresistance in nasopharyngeal carcinoma
- 15 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessEBV-LMP1 stabilizes circadian CRY2 to drive immune escape and chemoresistance in nasopharyngeal carcinoma
- 24 June 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 418, 111622
Dual roles and therapeutic potential of ALDH3 family members in cancer
- 24 June 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 418, 111622
Dual roles and therapeutic potential of ALDH3 family members in cancer
- 5 August 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (5) , 189166
Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy
- 5 August 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (5) , 189166
Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy
- 16 November 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1878 (6) , 189023
Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities
- 16 November 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1878 (6) , 189023
Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities
- Open Access
- 16 February 2022
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 171, 106143
Corrigendum to ’ Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers’[European Journal of Pharmaceutical Sciences 162 (2021) 105815]
- 16 February 2022
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 171, 106143
Open AccessCorrigendum to ’ Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers’[European Journal of Pharmaceutical Sciences 162 (2021) 105815]
- 1 December 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 89 (1) , 141-148
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers
Purpose Fuzuloparib (AiRuiYiTM, formerly fluzoparib, SHR3162) is a new orally active poly adenosine diphosphate ribose polymerase (PARP) inhibitor. It has multiple pharmacological activities in breast, ovarian, and prostatic cancer. Fuzuloparib is mainly metabolized through the enzyme CYP3A4 may slow fuzuloparib metabolism and increase its concentrations in blood. We evaluated the pharmacokinetics and tolerability of fuzuloparib by fluconazole, which is a broad antifungal agent and a moderate inhibitor of CYP3A4. Methods In this study, the effects of CYP3A4 inhibition on the pharmacokinetics of fuzuloparib were assessed in a total of 20 healthy Chinese male subjects in an open-label, two-period, single-sequence, crossover study. Results Pharmacokinetic parameters, including the maximal plasma concentration (Cmax), the plasma concentration–time curve from time 0 to last measurable area under concentration (AUC0−t), and from time 0 to infinity (AUC0−∞), were increased by 32.4%, 104.5%, and 109.6%, with corresponding 90% confidence intervals of (23–43%), (93–116%), and (98–122%), respectively, when fluconazole was combined with fuzuloparib compared to fuzuloparib alone. There was also a slight increase in the incidence of treatment emergent adverse events, including hyperlipidemia and elevated aspartate transaminase. Conclusion The fuzuloparib is 150 mg b.i.d in clinics use. Our results suggest that fuzuloparib could well be tolerated when administered as a single 20 mg oral dose alone or co-administered with 400 mg fluconazole in healthy male subjects. It is recommended to avoid using moderate CYP3A4 inhibitors together with fuzuloparib or instead of 50 mg when necessary.
- 1 December 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 89 (1) , 141-148
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers
Purpose Fuzuloparib (AiRuiYiTM, formerly fluzoparib, SHR3162) is a new orally active poly adenosine diphosphate ribose polymerase (PARP) inhibitor. It has multiple pharmacological activities in breast, ovarian, and prostatic cancer. Fuzuloparib is mainly metabolized through the enzyme CYP3A4 may slow fuzuloparib metabolism and increase its concentrations in blood. We evaluated the pharmacokinetics and tolerability of fuzuloparib by fluconazole, which is a broad antifungal agent and a moderate inhibitor of CYP3A4. Methods In this study, the effects of CYP3A4 inhibition on the pharmacokinetics of fuzuloparib were assessed in a total of 20 healthy Chinese male subjects in an open-label, two-period, single-sequence, crossover study. Results Pharmacokinetic parameters, including the maximal plasma concentration (Cmax), the plasma concentration–time curve from time 0 to last measurable area under concentration (AUC0−t), and from time 0 to infinity (AUC0−∞), were increased by 32.4%, 104.5%, and 109.6%, with corresponding 90% confidence intervals of (23–43%), (93–116%), and (98–122%), respectively, when fluconazole was combined with fuzuloparib compared to fuzuloparib alone. There was also a slight increase in the incidence of treatment emergent adverse events, including hyperlipidemia and elevated aspartate transaminase. Conclusion The fuzuloparib is 150 mg b.i.d in clinics use. Our results suggest that fuzuloparib could well be tolerated when administered as a single 20 mg oral dose alone or co-administered with 400 mg fluconazole in healthy male subjects. It is recommended to avoid using moderate CYP3A4 inhibitors together with fuzuloparib or instead of 50 mg when necessary.